Genzyme gets broad approval for Seprafilm
This article was originally published in Clinica
Executive Summary
US biotechnology company Genzyme has received unexpectedly broad approval for its surgical adhesion preventative, Seprafilm. The FDA has granted approval for the bioresorbable membrane to be used in any open abdominal or pelvic surgery, despite the lack of any long-term data showing a reduction in complications. Two clinical trials have shown that Seprafilm reduces adhesion formation by about 50%.